CVS to offer uninsured patients free flu shots
WOONSOCKET, R.I. CVS Caremark is partnering with nonprofit Direct Relief USA to offer up to $5 million in free flu shots to community clinic and health center patients who lack health insurance, the company announced on Wednesday.
Direct Relief USA works with 1,100 clinics and health centers in all 50 states, providing them with free medications and supplies for their low-income and uninsured patients. Most of the facilities in Direct Relief’s network are affiliated with either the National Association of Community Health Centers or the National Association of Free Clinics. CVS Caremark and Direct Relief USA will distribute vouchers redeemable for a free flu shot at any CVS/pharmacy or MinuteClinic to participating clinics and health centers. These facilities will identify uninsured individuals from their existing patient populations in order to provide them with a free flu shot voucher.
Beginning Sept. 20, CVS free flu shot vouchers for the uninsured will be available at participating community clinic and health centers for their existing patients. Names and locations of participating clinics will be made available on Sept. 20.
"With every CVS/pharmacy and MinuteClinic location providing flu vaccinations this year, we want to make sure that as many people as possible have access to a flu shot, including patients for whom cost may be a barrier," stated Larry Merlo, president and COO of CVS Caremark. "The Centers for Disease Control and Prevention is recommending that everyone receive a flu shot this year. We are pleased to partner with Direct Relief USA to help accomplish that goal."
Bayer Consumer Care adds two products to One A Day line
MORRISTOWN, N.J. Bayer Consumer Care on Tuesday introduced two new gender-specific multivitamins: One A Day Menopause Formula and One A Day Men’s Pro Edge.
One A Day Menopause Formula is a complete multivitamin formulated with soy isoflavones to help address hot flashes and mild mood changes.
"It can often be a challenge for women going through this new life stage to get the nutrients they need," stated diet and nutrition expert Madelyn Fernstrom. "Even with a healthy diet, supplementation may be needed to get adequate amounts of the nutrients important to this age group, particularly vitamin D and calcium. This can help support a healthy lifestyle for women as they enter this stage of their lives."
In addition, women going through menopause now have a new resource for information. LiveMenopause.com is dedicated to providing information about menopause and connecting women to others who are going through this stage of life.
Meanwhile, One A Day Men’s Pro Edge is a complete multivitamin that contains high levels of magnesium and vitamins A, B, C and E.
"Because men who are physically active exert more energy, they have an increased need for some nutrients to help their bodies refuel," Fernstrom said. "Though diet is the first source for nutritional needs, supplementation with a multivitamin can help provide extra nutrients to support optimal health for the busy, active man."
Decision Resources: Market for Alzheimer’s disease drugs will expand
BURLINGTON, Mass. Biotech drugs for treating Alzheimer’s disease will more than triple the size of the market in several key countries over the next decade, according to a new report by industry research company Decision Resources.
The report showed that bapineuzumab, made by Johnson & Johnson and Pfizer, and Eli Lilly’s solanezumab will drive the market for Alzheimer’s drugs from 2009’s $4.3 billion to $13.3 billion in 2019 in the United States, Japan, the United Kingdom, Germany, France, Italy and Spain.
Whereas most current Alzheimer’s drugs are acetylcholinesterase inhibitors, or AChEIs, which treat the disease’s cognitive symptoms without modifying its course, the new drugs have the potential to slow the rate of neural degeneration and cognitive decline, according to the report. Still, sales of AChEIs will remain strong through the decade.
“Despite increased generic competition and the launch of more-expensive and potentially more-efficacious therapies, AChEI sales will be buoyed through 2019,” Decision Resources director Bethany Kiernan said. “This will be largely due to an overall market expansion driven by increases in the number of drug-treated patients but also, to a lesser extent, by the launch of new formulations of branded AChEIs.”